Radar on Specialty Pharmacy

Stelara Isn’t Only High-Profile Drug With Biosimilars Expected in 2025

  • Jan 09
    Popup Image

    Jan 09, 2025

    While industry experts point to the entrance of biosimilars of Johnson & Johnson Innovative Medicine’s Stelara (ustekinumab) as one of the top biosimilar launches of 2025, multiple other similar agents are expected to enter the U.S. market. Some of the more high-profile ones include biosimilars of Amgen Inc.’s Prolia/Xgeva (denosumab), Alexion, AstraZeneca Rare Disease’s Soliris [(eculizumab) and Xolair (omalizumab) from the Roche Group’s Genentech USA, Inc. and Novartis Pharmaceuticals Corp. In addition, several generic specialty drugs are expected to become available as well, representing potentially more savings for payers. Industry experts told AIS Health, a division of MMIT, what they expect to see in the biosimilar and specialty generic areas over the next year. (Editor’s note: These comments have been edited for length and clarity.) 

    Read more
      • Radar on Specialty Pharmacy
    © 2024 MMIT

    • Angela Maas

    Angela has an extensive background of editing, reporting and writing for trade and consumer publications. She has written Radar on Specialty Pharmacy since she joined AIS Health in 2005 and has broad knowledge of the various issues at play within the space. She also has written for Spotlight on Market Access since its 2017 launch. Before joining AIS Health, she was managing editor at Employee Benefit News and Employee Benefit News Canada and managing editor at Hem Aware (a hemophilia publication), Lupus Living and Momentum (a multiple sclerosis publication). She has a B.A. in English and an M.A. in British literature from Arizona State University.

    Back to Radar on Specialty Pharmacy

Related Posts

The Latest
Premium Categories
Meet Our Reporters

Lauren Flynn Kelly

Executive Editor, AIS Health, and Managing Editor, Radar on Medicare Advantage

View Lauren Flynn Kelly's Profile

Angela Maas

Managing Editor, Radar on Specialty Pharmacy and Spotlight on Market Access

View Angela Maas's Profile

Leslie Small

Managing Editor, Health Plan Weekly and Radar on Drug Benefits

View Leslie Small's Profile

Tim Casey

Reporter, Health Plan Weekly and Radar on Drug Benefits

View Tim Casey’s Profile

Carina Belles

Reporter, Radar on Medicare Advantage and Spotlight on Market Access

View Carina Belles's Profile

Jinghong Chen

Reporter, Health Plan Weekly and Radar on Drug Benefits

View Jinghong Chen's Profile

Jill Drachenberg

Reporter, Health Plan Weekly and Radar on Drug Benefits

View Jill Drachenberg's Profile

Meet Our Reporters

Lauren Flynn Kelly

Executive Editor, AIS Health, and Managing Editor, Radar on Medicare Advantage

View Lauren Flynn Kelly's Profile

Angela Maas

Managing Editor, Radar on Specialty Pharmacy and Spotlight on Market Access

View Angela Maas's Profile

Leslie Small

Managing Editor, Health Plan Weekly and Radar on Drug Benefits

View Leslie Small's Profile

Tim Casey

Reporter, Health Plan Weekly and Radar on Drug Benefits

View Tim Casey’s Profile

Carina Belles

Reporter, Radar on Medicare Advantage and Spotlight on Market Access

View Carina Belles's Profile

Jinghong Chen

Reporter, Health Plan Weekly and Radar on Drug Benefits

View Jinghong Chen's Profile

Jill Drachenberg

Reporter, Health Plan Weekly and Radar on Drug Benefits

View Jill Drachenberg's Profile

Tags
Biosimilars
Specialty Drugs
Drug Pricing
Market Access
Drug Approvals
FDA
×

PREMIUM CONTENT AND PREMIUM INSIGHTS

To gain access to this article you need to have a Premium Subscription.
Click the link below to access today!